2017, Number S1
<< Back Next >>
Rev Mex Anest 2017; 40 (S1)
Interventional management in headaches
Chejne-Gómez F, Guajardo-Rosas J, Ayón-Villanueva H, Ramos-Alaniz A, Juárez-Lemus Á
Language: Spanish
References: 7
Page: 8-9
PDF size: 135.41 Kb.
Text Extraction
No abstract.
REFERENCES
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. 3rd ed. (Beta version). Cephalalgia. 2013;33:629-808.
Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53:427-436.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.
Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56- week PREEMPT clinical program. Headache. 2011;51:1358-1373.
Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697-704.
Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalalgia. 2014;34:382-391.
Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. The Lancet Neurol. 2012;11:708-719.
Full text